6-氯-2-甲氧基-4-甲基吡啶-3-腈 | 243469-65-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-氯-2-甲氧基-4-甲基吡啶-3-腈
• 英文名称: 6-chloro-2-methoxy-4-methylnicotinonitrile
• 英文别名: 6-chloro-2-methoxy-4-methylpyridine-3-carbonitrile
• CAS: 243469-65-0
• 化学式: C₈H₇ClN₂O
• 分子量: 182.609
• InChiKey: VJNGVKNSXGZARW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  45.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  6-氯-2-甲氧基-4-甲基吡啶-3-腈 在 dimethyl sulfide borane 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 14.0h， 生成 tert-butyl N-[(6-chloro-2-methoxy-4-methyl-3-pyridyl)methyl]carbamate
  参考文献：
  名称：

  Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time

  摘要：

  Histone methyltransferase EZH2, which is the catalytic subunit of the PRC2 complex, catalyzes the methylation of histone H3K27-a transcriptionally repressive post-translational modification (PTM). EZH2 is commonly mutated in hematologic malignancies and frequently overexpressed in solid tumors, where its expression level often correlates with poor prognosis. First generation EZH2 inhibitors are beginning to show clinical benefit, and we believe that a second generation EZH2 inhibitor could further build upon this foundation to fully realize the therapeutic potential of EZH2 inhibition. During our medicinal chemistry campaign, we identified 4-thiomethyl pyridone as a key modification that led to significantly increased potency and prolonged residence time. Leveraging this finding, we optimized a series of EZH2 inhibitors, with enhanced antitumor activity and improved physiochemical properties, which have the potential to expand the clinical use of EZH2 inhibition.

  DOI：

  10.1021/acsmedchemlett.0c00045
• 作为产物：
  描述：

  2,6-二羟基-3-氰基-4-甲基吡啶 在 三氯氧磷 作用下， 以 甲醇 为溶剂， 反应 11.0h， 生成 6-氯-2-甲氧基-4-甲基吡啶-3-腈
  参考文献：
  名称：

  Design, Synthesis, and Pharmacological Evaluation of Second Generation EZH2 Inhibitors with Long Residence Time

  摘要：

  Histone methyltransferase EZH2, which is the catalytic subunit of the PRC2 complex, catalyzes the methylation of histone H3K27-a transcriptionally repressive post-translational modification (PTM). EZH2 is commonly mutated in hematologic malignancies and frequently overexpressed in solid tumors, where its expression level often correlates with poor prognosis. First generation EZH2 inhibitors are beginning to show clinical benefit, and we believe that a second generation EZH2 inhibitor could further build upon this foundation to fully realize the therapeutic potential of EZH2 inhibition. During our medicinal chemistry campaign, we identified 4-thiomethyl pyridone as a key modification that led to significantly increased potency and prolonged residence time. Leveraging this finding, we optimized a series of EZH2 inhibitors, with enhanced antitumor activity and improved physiochemical properties, which have the potential to expand the clinical use of EZH2 inhibition.

  DOI：

  10.1021/acsmedchemlett.0c00045

文献信息

• [EN] NEW TRPA1 ANTAGONISTS<br/>[FR] NOUVEAUX ANTAGONISTES DE TRPA1
  申请人：ALMIRALL SA

  公开号：WO2017060488A1

  公开（公告）日：2017-04-13

  The present invention relates to compounds of Formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by TRPA1 channel inhibition or antagonism.

  本发明涉及式(I)的化合物，以及制备这种化合物的方法，以及它们在治疗通过TRPA1通道抑制或拮抗可改善的病理状况或疾病中的用途。
• [EN] SUBSTITUTED NITROGEN CONTAINING COMPOUNDS<br/>[FR] COMPOSÉS CONTENANT DE L'AZOTE SUBSTITUÉ
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018222795A1

  公开（公告）日：2018-12-06

  Disclosed are compounds of Formula (I): or a salt thereof, Formula (II) wherein R1 is: or; each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

  揭示了以下式（I）的化合物或其盐，式（II）其中R1是：或；每个W独立地是NR1b或O；Z是键或CHR1d；以及R1、R2、Rd、R3a、R3b、L1、B、V、Y和n在此处被定义。还揭示了将这些化合物用作ROMK抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗心血管疾病方面是有用的。
• [EN] NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME<br/>[FR] NOUVEAUX DERIVES DE PYRIDINE, LEUR PROCEDE DE PREPARATION ET COMPOSITION PHARMACEUTIQUE EN CONTENANT
  申请人：SK CHEMICALS CO LTD

  公开号：WO2005063768A1

  公开（公告）日：2005-07-14

  This invention relates to novel pyridine derivatives having an inhibitory effect on production of cytokines, which are involved in inflammatory responses, thus suggesting its usefulness as therapeutic agents for treating diseases related to inflammation, immune, chronic inflammation as well as an agent having an anti-inflammatory and analgesic effect. Further, this invention relates to a method of manufacturing the same and a pharmaceutical composition containing the same.

  这项发明涉及具有抑制细胞因子产生作用的新型吡啶衍生物，这些细胞因子参与炎症反应，因此表明其可用作治疗与炎症、免疫、慢性炎症相关疾病的治疗剂，同时具有抗炎和镇痛作用的药剂。此外，这项发明涉及制造该化合物的方法和含有该化合物的药物组合物。
• Studies on the preparation of 3,4-disubstituted 2-methoxypyridines
  作者：Marcelo M. M. Pelisson、Gil Valdo José Da Silva、Derrick L. J. Clive、Don M. Coltart、Fraser A. Hof

  DOI：10.1002/jhet.5570360313

  日期：1999.5

  The synthesis of 2-methoxy-4-methylpyridine-3-carbonitrile (3) and its conversion, by way of alkylation of the C(4) methyl group, into the pyrodyl acetic acid ester 6 is described.

  描述了2-甲氧基-4-甲基吡啶-3-甲腈（3）的合成及其通过C（4）甲基的烷基化转化为吡啶基乙酸酯6的方法。
• [EN] 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES FOR TREATING NEUROLOGICAL AND NEURODEGENERATIVE DISEASES<br/>[FR] DÉRIVÉS DE 5,7-DIHYDRO-PYRROLO-PYRIDINE POUR LE TRAITEMENT DE MALADIES NEUROLOGIQUES ET NEURODÉGÉNÉRATIVES
  申请人：PFIZER

  公开号：WO2018002760A1

  公开（公告）日：2018-01-04

  The present invention provides, in part, compounds of Formula (I): or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N- oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4- associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

  本发明部分提供了Formula (I)的化合物：或其N-氧化物，或该化合物或N-氧化物的药用盐，其中：R1、R2、L、A和E如本文所述；用于制备的过程；用于制备的中间体；以及含有这种化合物、N-氧化物或盐的组合物，以及它们用于治疗M4介导的（或M4相关的）疾病，例如阿尔茨海默病、精神分裂症（例如其认知和消极症状）、疼痛、成瘾和睡眠障碍。